Amplia Therapeutics has reported data demonstrating the efficacy of AMP945 in a preclinical model of pancreatic cancer when used along with FOLFIRINOX treatment.
AMP945 is an orally bioavailable small molecule FAK inhibitor while FOLFIRINOX is a combination of four chemotherapies used for treating pancreatic cancer.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Preclinical studies were conducted at the Garvan Institute of Medical Research in Sydney, Australia. They demonstrated that mice treated with AMP945 as well as FOLFIRINOX showed improved overall survival against FOLFIRINOX alone.
AMP945 was administered in the days preceding FOLFIRINOX treatment (given on a 12-day cycle) which showed an increase in survival compared to FOLFIRINOX-only treated mice.
Amplia CEO and managing director Dr Chris Burns said: “The exciting results from this mouse study further indicate the potential of AMP945 in pancreatic cancer treatment when used in combination with standard-of-care therapies.
“In light of this data, we have filed a patent to cover the use of FAK inhibitors, and particularly AMP945, in combination with FOLFIRINOX and related treatment regimes.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPreviously reported preclinical data also demonstrated the benefit of AMP945, gemcitabine and nab-paclitaxel combination.
Additionally, AMP945 showed promising activity in pancreatic cancer models with the two most common first-line chemotherapy regimens to treat the disease.
At present, the compound is undergoing the Phase Ib/IIa ACCENT trial in patients with pancreatic cancer along with gemcitabine and nab-paclitaxel in Australia.
